Statin side effects

The atorvastatin label pools 16,066 patients from its placebo-controlled trials, 8,755 on the drug and 7,311 on placebo, with a median treatment duration of 53 weeks. Out of every 100 people on the drug, against 100 on placebo (Lipitor label):

• Nasopharyngitis: 8.3, against 8.2
• Arthralgia: 6.9, against 6.5
• Diarrhea: 6.8, against 6.3
• Pain in extremity: 6.0, against 5.9
• Urinary tract infection: 5.7, against 5.6
• Dyspepsia: 4.7, against 4.3
• Nausea: 4.0, against 3.5
• Musculoskeletal pain: 3.8, against 3.6
• Muscle spasms: 3.6, against 3.0
• Myalgia: 3.5, against 3.1
• Insomnia: 3.0, against 2.9

The reactions that led people to quit more often than on placebo make a shorter list: myalgia at 0.7%, diarrhea at 0.5%, nausea at 0.4%, alanine aminotransferase increase at 0.4%, and hepatic enzyme increase at 0.4% (Lipitor label).

Rosuvastatin reports its own 12-week trials the same way, 744 people on 5 to 40 mg against 382 on placebo: headache 5.5 against 5.0, nausea 3.4 against 3.1, myalgia 2.8 against 1.3, asthenia 2.7 against 2.6, constipation 2.4 against 2.4 (Crestor label). Its longer trials raise both columns together. In METEOR, at 40 mg over a mean of 1.7 years, myalgia was 12.7 against 12.1 and increased CPK was 2.6 against 0.7 (Crestor label). In JUPITER, at 20 mg in 8,901 people against 8,901 on placebo over a mean of two years, 7.6% on the drug reported muscle aches and 6.6% on the sugar pill did (Crestor label).

About 60 adults who had already stopped a statin because of side effects took 12 monthly jars over a year, four containing atorvastatin 20 mg daily, four containing placebo, and four empty, and rated their symptoms daily from 0 to 100 without knowing which jar they were on. In the AHA's own words, "90% of the symptoms that were reported when participants were taking a statin were also reported when the participants unknowingly took the placebo tablets," and "Patients were just as likely to need to temporarily stop placebo tablets due to intolerable side effects as the statin tablets" (AHA, November 2020).

The symptoms were real. The lead author's line in the same release is the one to keep: "Patients should be taken seriously when they report side effects, because they are genuinely suffering. We were surprised how severe some of the symptoms experienced during the study were. Twenty-four patients, on 71 occasions, had symptoms so severe they had to stop taking their tablets temporarily. However, this occurred just as frequently when patients took a placebo as when they took a statin" (AHA, November 2020).

Two footnotes belong with it. The trial could only recruit people whose previous statin symptoms had started within two weeks of the tablets (AHA, November 2020). And six months after the participants completed the trial, half of them had restarted taking a statin medication and were still taking it (AHA, November 2020). The AHA's summary of its 2018 scientific statement puts the trial evidence the same way: "Muscle pain and weakness were rare complaints in statin clinical trials. When muscle symptoms do occur, they often are linked to the drug's dosage" (AHA, December 2018).

Both labels open the same way. The drug "may cause myopathy (muscle pain, tenderness, or weakness associated with elevated creatine kinase [CK]) and rhabdomyolysis. Acute kidney injury secondary to myoglobinuria and rare fatalities have occurred as a result of rhabdomyolysis in patients treated with statins" (Lipitor label, Crestor label).

Risk factors for myopathy include age 65 years or greater, uncontrolled hypothyroidism, renal impairment, concomitant use with certain other drugs including other lipid-lowering therapies, and a higher dosage (Lipitor label). Rosuvastatin adds that Asian patients on the drug may be at higher risk for myopathy, and that the risk is greater at 40 mg daily than at lower dosages (Crestor label). Simvastatin names a different group, saying Chinese patients on the drug may be at higher risk for myopathy (Zocor label).

Simvastatin is the label that puts numbers on it. Across 24,747 treated patients with a median follow-up of four years, myopathy defined as unexplained muscle weakness, pain, or tenderness with CK above ten times the upper limit of normal occurred in approximately 0.03%, 0.08%, and 0.61% of patients at 20 mg, 40 mg, and 80 mg daily (Zocor label). In a second study of 12,064 patients over 6.7 years, rhabdomyolysis defined as myopathy with CK above 40 times the upper limit of normal occurred in approximately 0% at 20 mg and 0.4% at 80 mg (Zocor label). At the low dose that is roughly three people in ten thousand, and at the highest dose roughly six in a thousand.

What the labels ask of a prescriber is short: "Discontinue LIPITOR if markedly elevated CK levels occur or if myopathy is either diagnosed or suspected. Muscle symptoms and CK elevations may resolve if LIPITOR is discontinued" (Lipitor label, and the same sentence in the Crestor label under its own name). Neither label sets a routine CK monitoring schedule for people without symptoms, and neither says how long symptoms take to fade after a stop, so that timing is a question for the prescriber. The Lipitor label also calls for a temporary stop during an acute or serious condition at high risk of kidney failure from rhabdomyolysis, naming sepsis, shock, severe hypovolemia, major surgery, trauma, severe metabolic, endocrine, or electrolyte disorders, and uncontrolled epilepsy (Lipitor label).

One rare reaction gets its own paragraph in both labels. Immune-mediated necrotizing myopathy is an autoimmune myopathy characterized by proximal muscle weakness and elevated serum creatine kinase that persists despite discontinuation of statin treatment (Lipitor label, Crestor label). That persistence is why the patient leaflet asks you to tell your doctor about muscle problems that do not go away after your doctor has told you to stop taking the drug (Lipitor Patient Information).

Routine periodic liver monitoring came off statin labels in 2012. FDA's announcement said labels "have been revised to remove the need for routine periodic monitoring of liver enzymes in patients taking statins. The labels now recommend that liver enzyme tests should be performed before starting statin therapy and as clinically indicated thereafter. FDA has concluded that serious liver injury with statins is rare and unpredictable in individual patients, and that routine periodic monitoring of liver enzymes does not appear to be effective in detecting or preventing serious liver injury" (FDA, 2012). The current labels match: "Consider liver enzyme testing before LIPITOR initiation and when clinically indicated thereafter" (Lipitor label), and the Crestor label carries the same sentence under its own name.

The trial numbers behind that decision are small. Persistent increases to more than three times the upper limit of normal in serum transaminases occurred in approximately 0.7% of patients receiving atorvastatin, and by dose the incidence was 0.2%, 0.2%, 0.6%, and 2.3% at 10, 20, 40, and 80 mg (Lipitor label). For rosuvastatin it was 1.1% of patients on the drug against 0.5% on placebo (Crestor label).

Most of those rises settled without anything being stopped. In most cases the changes appeared soon after initiation, were transient, were not accompanied by symptoms, and resolved or improved on continued therapy or after a brief interruption in therapy (Lipitor label, Crestor label). Upon dose reduction, drug interruption, or discontinuation, transaminase levels returned to or near pretreatment levels without sequelae, and eighteen of thirty patients with persistent elevations continued treatment at a reduced dose (Lipitor label). For simvastatin, the majority of elevated transaminases leading to treatment discontinuation occurred within the first year (Zocor label).

The symptoms that mean call are the same on every source. Promptly report fatigue, anorexia, right upper abdominal discomfort, dark urine or jaundice (Lipitor label, Crestor label), which FDA writes for a reader as unusual fatigue or weakness, loss of appetite, upper belly pain, dark-colored urine, or yellowing of the skin or the whites of the eyes (FDA, 2012).

The labels carry a dedicated warning about it. "Increases in HbA1c and fasting serum glucose levels have been reported with statins, including LIPITOR. Optimize lifestyle measures, including regular exercise, maintaining a healthy body weight, and making healthy food choices" (Lipitor label). Rosuvastatin adds one clause: based on clinical trial data, in some instances these increases may exceed the threshold for the diagnosis of diabetes mellitus (Crestor label).

The trial numbers are modest and worth seeing next to each other. In JUPITER, diabetes mellitus was reported in 2.8% of patients on rosuvastatin against 2.3% on placebo, and mean HbA1c was significantly increased by 0.1% against placebo (Crestor label). In SPARCL, which ran atorvastatin 80 mg against placebo over a median 4.9 years in people who had already had a stroke or TIA, diabetes was reported as an adverse reaction in 6.1% of the drug group and 3.8% of the placebo group (Lipitor label). That was the 80 mg dose in a high-risk population rather than the starting dose most people are handed.

At the class level, FDA cited a meta-analysis by Sattar and colleagues covering 13 statin trials and 91,140 participants, which reported a 9% increased risk for incident diabetes (odds ratio 1.09; 95% CI 1.02-1.17), and a second meta-analysis of 6 trials with 57,593 participants reporting a relative risk of 1.13 (95% CI 1.03-1.23) (FDA, 2012). FDA's own verdict on the trade-off sits in the same document: "FDA continues to believe that the cardiovascular benefits of statins outweigh these small increased risks" (FDA, 2012). The AHA reaches the same place from its 2018 statement, saying most people on the drugs already had a high risk for diabetes and that people with diabetes on statins see an insignificant increase in blood sugar levels (AHA, December 2018).

This one entered the labels in 2012, and the wording has not changed since. "There have been rare post-marketing reports of cognitive impairment (e.g., memory loss, forgetfulness, amnesia, memory impairment, confusion) associated with statin use. These reported symptoms are generally not serious and reversible upon statin discontinuation, with variable times to symptom onset (1 day to years) and symptom resolution (median of 3 weeks)" (FDA, 2012; Lipitor label; Crestor label). Those onset and resolution figures belong to cognitive symptoms alone and do not carry over to muscle aches.

When FDA looked at the reports, it found individuals over the age of 50 with notable but ill-defined memory loss that reversed on stopping, and it added that the cases did not appear to be associated with fixed or progressive dementia, such as Alzheimer's disease, and that data from the observational studies and clinical trials did not suggest that cognitive changes associated with statin use are common or lead to clinically significant cognitive decline (FDA, 2012). MedlinePlus lists forgetfulness or memory loss and confusion among atorvastatin's ordinary side effects, in the same list as diarrhea, heartburn, gas, and joint pain (MedlinePlus).

The rule you were told depends on which of the three you were handed, and the difference is real. For simvastatin the instruction has no volume allowance: grapefruit juice can raise the plasma levels of simvastatin and may increase the risk of myopathy and rhabdomyolysis, so avoid grapefruit juice while taking it (Zocor label). For atorvastatin the label sets a limit instead, saying grapefruit juice consumption, especially excessive consumption of more than 1.2 liters daily, can raise plasma levels and may increase the risk of myopathy and rhabdomyolysis, and instructing patients to avoid drinking more than 1.2 liters of grapefruit juice each day (Lipitor label, Lipitor Patient Information). For rosuvastatin the label does not raise grapefruit at all; the word does not appear in it (Crestor label).

MedlinePlus keeps the consumer version simple and sends the question back to the prescriber: talk to your doctor about eating grapefruit and drinking grapefruit juice while taking this medication, and ask about the safe use of alcoholic beverages, because alcohol can increase the risk of serious side effects (MedlinePlus).

Some combinations the atorvastatin label rules out outright. Concomitant use of cyclosporine or gemfibrozil with it is not recommended, and neither is tipranavir plus ritonavir or glecaprevir plus pibrentasvir (Lipitor label). Others come with a ceiling: do not exceed 20 mg with saquinavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, fosamprenavir plus ritonavir, elbasvir plus grazoprevir, letermovir, clarithromycin, or itraconazole, and do not exceed 40 mg with nelfinavir (Lipitor label). The antibiotic and antifungal list it prints is erythromycin, clarithromycin, itraconazole, ketoconazole, posaconazole, and voriconazole (Lipitor label).

Cases of myopathy and rhabdomyolysis have also been reported with atorvastatin taken alongside lipid modifying doses of more than 1 gram a day of niacin, and alongside fibrates, colchicine, and ledipasvir plus sofosbuvir (Lipitor label). Rosuvastatin's list is shorter and points the same way: cyclosporine or gemfibrozil is not recommended, dosage modifications are recommended with certain antiviral medications, darolutamide, and regorafenib, and niacin, fibrates, and colchicine may also increase the risk of myopathy and rhabdomyolysis (Crestor label).

Two smaller ones are easy to miss. Rosuvastatin has a timing rule the others do not: when taking it with an aluminum and magnesium hydroxide combination antacid, take the statin at least 2 hours before the antacid (Crestor label). And atorvastatin pushes in the other direction on two common drugs, since it may increase plasma levels of norethindrone and ethinyl estradiol, and may increase digoxin plasma levels, which the label says to monitor (Lipitor label).

Four sources answer this and they do not fully agree, so here is each one. The atorvastatin patient leaflet says to take it as soon as you remember, but not to take it if it has been more than 12 hours since you missed your last dose, and to wait and take the next dose at your regular time (Lipitor Patient Information). MedlinePlus says the opposite about the late dose, telling you to skip the missed dose and continue your regular dosing schedule (MedlinePlus). The rosuvastatin label says not to take an extra dose and just resume the usual schedule (Crestor label). The simvastatin leaflet says to take it as soon as you remember, and if you do not remember until it is time for your next dose, to skip the missed one and go back to your regular schedule (Zocor Patient Information).

What all four agree on is the part that matters: never take two doses at the same time to make up for one, and take the next one on schedule (Lipitor Patient Information, MedlinePlus, Crestor label, Zocor Patient Information). Which of the two rules about a late dose applies to you is a question for your prescriber or pharmacist.

Both labels give the same window in their dosage section, saying to assess LDL-C when clinically appropriate, as early as 4 weeks after starting, and adjust dosage if necessary (Lipitor label, Crestor label). The pharmacology explains why the follow-up lands there rather than at six months, since the reduction from rosuvastatin is usually achieved by 4 weeks and is maintained after that (Crestor label).

Every source on this page says the same thing about stopping, and says it plainly. Continue to take atorvastatin even if you feel well, and do not stop taking it without talking to your doctor (MedlinePlus). Take it exactly as your doctor tells you, and do not change your dose or stop without talking to your doctor (Lipitor Patient Information). Follow directions, report any side effects, and don't stop treatment without talking to your healthcare professional (AHA, March 2026). The co-author of the AHA's statin safety statement put the reason in one line: "Patients shouldn't stop taking statins without consulting their doctor because that could be dangerous" (AHA, December 2018).

The AHA's guidance for people worried about taking them is to talk to their health care providers about finding the best medication for them (AHA, December 2018), and the AHA's cholesterol medications page says statins are often the first medication recommended to lower LDL, naming atorvastatin, rosuvastatin, and simvastatin as examples (AHA, March 2026).

I never change your dose, never tell you to stop one, and never diagnose. What I do is text you at the time you take it, ask every day how the aches and the tiredness are, keep the answers with their dates, and hold what you tell me against the label's report-promptly list, so an unexplained muscle pain with a fever gets noticed on the day it happens rather than at the next visit. I also keep the four-week follow-up on the calendar and read the weeks back to you before the appointment.

No clinician reviewed this page. It restates the FDA labels for atorvastatin, rosuvastatin, and simvastatin, FDA's 2012 safety communication, MedlinePlus, the NHS, and the AHA pages linked below, and those are the documents to trust over anything here.